[小儿急性淋巴细胞白血病丸复发的临床特征和预后分析]

N Wang1, Y Y Gao1, B Q Qi1

  • 1Pediatric Blood Diseases Center, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Tianjin Institutes of Health Science, Tianjin 300020, China.

概括

小儿急性淋巴细胞白血病 (ALL) 在丸中复发的预后不好,通常发生在诊断后3年左右. 然而,ETV6-RUNX1基因存在表明更好的结果,CAR-T细胞治疗显著提高了这些儿童的生存率.